SINOPHARM(HK:01099) Di Yi Cai Jing·2025-12-26 14:26Core Viewpoint - The development of the world's first oral six-valent reconfigured rotavirus live attenuated vaccine by China National Pharmaceutical Group marks a significant breakthrough in children's vaccine research and application in China, enhancing the child health protection system [1] Group 1: Vaccine Development - The vaccine has successfully completed the first dose administration in Wuhan, indicating progress in pediatric vaccine development [1] - It has undergone rigorous clinical trials, demonstrating safety and efficacy that meet international advanced vaccine standards [1] - The vaccine is expected to receive approval from the National Medical Products Administration by August 2025, classifying it as a new type of preventive biological product [1] Group 2: Market Position and Impact - This vaccine is noted to be the highest-priced and most widely covered rotavirus vaccine globally, providing comprehensive protection against acute gastroenteritis in infants and young children [1] - The introduction of this vaccine is anticipated to inject new momentum into the construction of child health protection systems in China [1]